Markets
SoundHound AI short sellers
(CSA Archives/Getty)

Shorts squeezed, SoundHound soars

The small-cap AI software company — a favorite of retail traders last year — is on track for its best day since December.

Score one for SoundHound AI, as the small-cap software company — and dreamboat of retail traders last year — soared Monday during an apparent short squeeze.

We say apparent, of course, because it’s impossible to conclusively say why any stock is moving at any particular moment.

But with no real news out for SoundHound Monday and the shares up roughly 20%, the massive amount of short interest in the stock (which we’ve spotlighted previously) clearly comes in for consideration as the catalyst.

As a refresher, short squeezes occur when short sellers — traders who borrow a stock, sell it, and hope to repurchase it at a lower price — are surprised when the shares actually rise. They then rush, en masse, to buy the stock, adding to upward momentum on prices and creating exaggerated price movements.

At last glance, stock out on loan to short sellers accounted for more than 30% of the company’s tradable float, a whopping indication the company, which for much of the last year dealt with lingering questions over its accounting practices, continues to face scrutiny from the market.

Its most recent earnings report, which fell short of Wall Street expectations for sales growth, hasn’t settled matters.

Still, the bravado of SoundHound CEO Keyvan Mohajer, who told short sellers to “bring it,” has been rewarded today as the shares have been lifted by the broad-based relief rally in AI and tech stocks after the announcement of a trade truce between China and the US.

Shortly before 12 p.m. ET, SoundHound was the top gainer in the Goldman Sachs basket of most heavily shorted stocks in the information technology space.

More Markets

See all Markets
markets

Spectrum-owner Charter Communications is on pace for its worst day ever as broadband numbers and Q1 results disappoint

Cable and broadband company Charter Communications is on pace for its worst-ever trading day on Friday, as investors dump the stock following its Q1 results and forward guidance.

Charter, which owns Spectrum, reported adjusted earnings of $9.17 per share, below Wall Street estimates of $9.96 per share from analysts polled by FactSet. On the company’s earnings call, CFO Jessica Fischer appeared to lower its full-year revenue per user guidance.

“It'll be close either way in terms of whether we end up with net growth,” said Fischer.

The company lost 120,000 internet subscribers in the quarter, deeper than the expected 94,800 and double its loss from the same period last year. That news comes one day after Comcast’s earnings provided a bit of optimism for broadband as a category: the company reported Q1 losses of 65,000, significantly improving from 183,000 losses in the same quarter last year. Comcast is down more than 10%, on pace for its worst day since January 2025.

markets

Nvidia poised to snap longest run without a record close since the AI boom began

The stock price of the company responsible for the brains of the AI boom is finally showing some brawn again.

Nvidia, the world’s most valuable company, is poised to close at a record high for the first time since October 29, 2025, on Friday (if it ends above $207.04).

The AI chip trade is on fire, with the Philadelphia Semiconductor Index slated to deliver its 18th consecutive gain as Intel’s robust results and outlook juice the entire ecosystem. Hyperscalers report earnings next week, and their capex guidance can be thought of as the earnings guidance for Nvidia and other AI suppliers for the quarters to come.

This would end Nvidia’s longest stretch without a record close since the unofficial start of the AI boom (when the chip designer delivered blowout quarterly results in May 2023).

(Sorry if I jinx this!)

markets

Lilly slips after prescriptions for its weight-loss pill come in below expectations in second week

Eli Lilly fell on Friday after prescription data for its new weight-loss pill, Foundayo, showed that it’s having a significantly slower rollout than its top competitor.

The pill was prescribed about 3,700 times in its second week, according to IQVIA data cited by Deutsche Bank analysts, compared to the roughly 8,000 they were expecting. Novo Nordisk’s Wegovy pill, which came out in January, hit over 18,000 prescriptions in its second week.

The FDA approved Foundayo on April 1 and shipments began on April 9. Deutsche analysts noted that Lilly’s GLP-1 injections, which currently outsell Novo’s, also had a slower start.

Lilly fell more than 4% after the numbers were released. Novo Nordisk rose more than 5%.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, Robinhood Derivatives, LLC, or Robinhood Money, LLC. Futures and event contracts are offered through Robinhood Derivatives, LLC.